2024-03-13 16:35:41
Metafora Biosystems obtains reimbursement in France of his first diagnostic aid test Glut1 transporter deficiency syndrome
Paris, France, March 11, 2024 – Metafora Biosystems, a healthtech that develops a platform for analyzing cellular metabolism, announces the official coverage by Health Insurance of its METAglut1™ test, for the early diagnosis of De Vivo disease or transporter deficiency encephalopathy type 1 glucose (Glut1DS). According to Ministry of Health and Prevention, METAglut1 is the first product to obtain definitive reimbursement through the Innovation Package. This device made it possible to set up a 30-month study to demonstrate the effectiveness of METAglut1 in the early detection of Glut1DS syndrome. It was carried out in more than 30 pediatric and adult neurology centers in France. In May 2023, the High Authority for Health (HAS) published a positive recommendation for treatment on the basis of an Expected Level 2 Service Improvement. “This reimbursement is an important step for patients, healthcare professionals and the medical community as a whole,” says Vincent Petit, president of Metafora. “Thanks to reimbursement, we can ensure wider and fairer access to this diagnostic tool which can have a major impact on patients, by allowing healthcare professionals to correctly identify Glut1DS syndrome and implement quickly implements the appropriate treatment strategy. » METAglut1 is now available in two analysis laboratories in France, the Pharmacology Department of Bichat hospital (APHP, Paris) and the Cerba laboratory (Frépillon). This ensures optimal coverage of prescriptions on a national scale. This is a major breakthrough for Metafora, demonstrating the clinical impact of its technology platform. This makes it possible to detect dysfunctions of cellular metabolism, which can be the origin, or accompany, numerous diseases in different therapeutic areas: metabolic or inflammatory diseases, oncology. Metafora is also continuing work to design and validate new tests aimed at characterizing the metabolism of tumor and immune cells in certain cancers. Metafora plans to develop a range of tests to improve diagnosis and prognosis in the booming immuno-oncology market. About Glut1DS syndrome and METAglut1™ – diagnose to treat Glucose transporter deficiency type 1 encephalopathy (Glut1DS), also known as De Vivo disease, is a rare neurological condition that affects approximately 30,000 people in Europe and the United States, of whom less than 2 000 have been diagnosed. Patients with Glut1DS suffer from a defect in the uptake of glucose by brain cells, leading to seizures, abnormal movements, and often developmental delay. Treatment consists of implementing a ketogenic diet rich in fats, which significantly improves patients’ symptoms, especially when implemented at the first signs of the disease. The METAglut1 blood test can identify patients within 48 hours, which is much faster than current diagnostic tests, which rely on a lumbar puncture – an invasive procedure – and/or complex genetic analysis. A multicenter validation study, supported by the French Society of Pediatric Neurology (SFNP) and the French Society for the Study of Innate Errors of Metabolism (SFEIM), was published in Neurology in 2023. It shows that METAglut1 has a specificity close to 100% and a sensitivity of 80%. METAglut1 is the result of a collaboration between Metafora Biosystems, more than 30 hospital clinical trial centers including teams from AP-HP, the Cerba laboratory and the CNRS. About Metafora BiosystemsMetafora Biosystems is a healthtech that develops a platform for analyzing cellular metabolism. METAglut1™ is its first diagnostic aid test. Metafora’s technology allows healthcare professionals to detect cells whose energy metabolism is dysfunctional. This phenomenon can be the origin, or accompany, numerous diseases in different therapeutic areas: metabolic or inflammatory diseases, oncology. Metafora has established academic and industrial partnerships for the development of diagnostic products in oncology. Additionally, the company works to improve the clinical effectiveness of cell therapies and reduce the costs of their production.Metafora has also developed METAflow™, cytometry data analysis software embedding artificial intelligence in the cloud. This solution provides unparalleled reliability to users who face increasingly complex data flows, with the advent of numerous so-called single cell technologies. The first generation of METAflow will be launched soon, and regulatory work is underway to make it a clinical grade solution.Metafora, based in Paris (France) with 27 employees, received grants from Bpifrance to develop its technological platform and funding from the European Union’s Horizon 2020 research and innovation program, grant agreement no. 806038. company is a winner of the EIC Accelerator program of the European Commission.www.metafora-biosystems.com[Décision du 2 janvier 2024, JORF n°0038 du 15 février 2024, texte n°18]
1710348104
#METAglut1 #moved #innovation #package #reimbursement #common #law
